The U.S. Food and Drug Administration (FDA) approves adrabetadex, an injection using cyclodextrin, for infantile-onset Niemann-Pick disease type C (NPC), a rare and fatal pediatric neurodegenerative disorder. Multiple outlets report that analysis from a large, international clinical trial shows the treatment is associated with longer survival for participants with NPC.
The approval follows work described as building on research efforts that began about two decades earlier, involving the National Institutes of Health (NIH) and collaborators including Beren Therapeutics. Reporting also frames the decision in terms of the drug’s tested role in a population with a rapidly progressive course, and highlights that the therapy is designated for patients meeting specific eligibility criteria, including weight and age ranges. While outlets differ slightly in the brand naming and the detail they choose to foreground, they consistently describe the same regulatory outcome and clinical-trial premise: extended survival in infantile-onset NPC.